Pharos IBio Co Ltd

Pharos IBio Co Ltd maintains a strong liquidity position with KRW 25.5 billion in cash and equivalents, significantly exceeding liabilities of KRW 15.9 billion, resulting in a current ratio of 18.96. However, the company reported negative operating cash flow of KRW -8.35 billion and free cash flow of KRW -9.96 billion, indicating ongoing operational cash burn. Profitability metrics are negative, with a return on equity of -77.24% and return on assets of -36.01%, both well below industry norms for biotechnology firms. The company reported no revenue and a net loss of KRW -10.76 billion, reflecting the high costs of drug development and lack of commercialized products. The company operates as a single-segment entity focused on drug R&D, with no disclosed geographic revenue breakdown. Given the absence of revenue and the nature of its operations, geographic exposure cannot be quantified from available data. Outlook for the current fiscal year shows no revenue growth, with the company continuing to report zero revenue. The next fiscal year is expected to follow a similar trajectory, with no disclosed product commercialization timelines or revenue-generating milestones. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a debt-to-equity ratio of 0.57, suggesting moderate leverage. No dilution sources were identified in recent filings, and shares outstanding remain unchanged between basic and diluted shares. Recent filings and transcripts do not disclose material events or strategic shifts. The company remains focused on its pipeline of treatments for rare diseases, with no indication of near-term product approvals or partnerships.